Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest lidocaine Stories

2013-09-05 08:28:32

Data Evaluating Heated Lidocaine/Tetracaine Patch for the Treatment of Acute Musculoskeletal Pain to be Presented MISSISSAUGA, ON, Sept. 5, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 announced today that researchers are presenting scientific data related to the heated lidocaine/tetracaine...

2013-08-14 23:17:40

Precise Care offers new treatment for effective relief from chronic headaches and migraines. Orange County, CA (PRWEB) August 14, 2013 Precise Care recently became the first practice to offer sphenopalatine ganglion (SPG) block as a treatment for patients who suffer from chronic migraine headaches, cluster headaches, and chronic daily headaches. The treatment also may have a beneficial effect on moods, anxiety and post-traumatic stress disorder. “The development of a new soft catheter...

2013-07-23 08:30:22

LANGHORNE, Pennsylvania, July 23, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or the "Company") today announced the initiation of a preclinical proof-of-principle study of an experimental hydrogel patch containing lidocaine. Safety and tolerability of Alliqua's lidocaine hydrogel patches will be explored in an animal model. Further, the pharmacokinetic profile will be analyzed to determine the amount of systemic absorption and local lidocaine concentration in...

2013-07-10 16:26:37

MISSISSAUGA, ON and SOUDERTON, PA, July 10, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, and Galen US Incorporated, today announced that Nuvo and Nuvo's wholly owned subsidiary, ZARS Phama, Inc. and Galen have entered into a product acquisition and license agreement for Galen to acquire the exclusive rights to market and sell Nuvo's Synera patch throughout the...

2013-04-29 08:26:48

HUNTINGTON BEACH, Calif., April 29, 2013 /PRNewswire/ -- Absorption Pharmaceuticals announced today that the U.S. Patent and Trademark Office has indicated that it will grant a patent related to the use of its topical medication, Promescent, for premature ejaculation (PE). The patent protects novel lidocaine-only eutectic formulation which enables maximum absorption of the anesthetic through the skin's outer layer and provides men with improved ejaculatory control while maintaining great...

2013-04-23 08:33:26

MISSISSAUGA, ON, April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.  Marketing licenses have been...

2013-04-19 08:25:31

Data Evaluating Synera(®) for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON, April 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera(®) (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22(nd) Annual Meeting of the American Medical Society for Sports Medicine...

2013-03-11 08:27:05

MISSISSAUGA, ON, March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in...

2012-10-22 07:29:00

MISSISSAUGA, ON, Oct. 22, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Pliaglis® (lidocaine/tetracaine) 7%/7% Cream.  Nuvo has licensed worldwide...

2012-09-05 06:25:07

AACHEN, Germany, September 5, 2012 /PRNewswire/ -- Targeted Treatment for Patients Suffering from Postherpetic Neuralgia: It's a Control Thing - This press Information is meant exclusively for trade press. - We do not approve publication in lay press. Ask pain patients what they expect from their treatment and the answer is simple: "I want to sleep through the whole night," or, "I want to be able to walk with my wife." They want relief with minimal side...